EGFR and neoplasm: The cutting-edge technology of PI3K inhibitors promotes the precision and efficiency of tumor treatment through multidimensional innovation: dual target inhibitors (such as MTX-531) break through the limitations of single targets, synergistically inhibit the PI3K and EGFR signaling pathways, and double block the key driving factors of tumor proliferation and survival, significantly enhancing antitumor activity and reducing the risk of drug resistance [61].